Final Overall Survival and Long-Term Safety of Lorlatinib in Patients With ALK-Positive NSCLC From the Pivotal Phase 2 Study: A Brief Report
Details
Publication Year 2025-04,Volume 20,Issue #4,Page 513-520
Journal Title
Journal of Thoracic Oncology
Publication Type
Research article
Abstract
INTRODUCTION: Lorlatinib is a potent, brain-penetrant, third-generation inhibitor of anaplastic lymphoma kinase (ALK) and ROS1 tyrosine kinases with broad coverage of ALK resistance mutations. We present the overall survival (OS) and long-term safety of lorlatinib in patients with advanced ALK-positive NSCLC from the final analyses of the pivotal phase 2 study. METHODS: Adults with ALK-positive NSCLC, enrolled in expansion cohorts (EXPs) on the basis of prior therapy (EXP1-5), received lorlatinib 100 mg orally once daily in continuous 21-day cycles. The primary endpoint was the objective response rate; secondary endpoints included OS and safety. RESULTS: Thirty patients were enrolled in EXP1 (treatment naïve), 59 in EXP2-3A (disease progression after crizotinib ± chemotherapy), 28 in EXP3B (disease progression after one second-generation ALK tyrosine kinase inhibitor [TKI] ± chemotherapy), 111 in EXP4-5 (disease progression after ≥2 ALK TKIs ± chemotherapy), and 139 in EXP3B-5 (disease progression after ≥1 ALK TKI ± chemotherapy). Median OS was not reached (NR) (95% confidence interval [CI]: NR-NR) in EXP1, NR (95% CI: 51.5-NR) in EXP2-3A, 37.4 months (95% CI: 12.3-NR) in EXP3B, 19.2 months (95% CI: 15.4-30.2) in EXP4-5, and 20.7 months (95% CI: 16.1-30.3) in EXP3B-5. All-cause adverse events leading to dose reduction were reported in 77 patients (28%), temporary treatment discontinuation in 158 patients (57%), and permanent discontinuation in 35 patients (13%). CONCLUSIONS: After a minimum follow-up of five years, final analyses from the global phase 2 study confirmed substantial activity, prolonged OS, and generally consistent safety findings with lorlatinib in treatment-naïve and previously treated patients with ALK-positive NSCLC. CLINICALTRIALS: gov NCT01970865.
Publisher
Elsevier
Keywords
Humans; Male; Female; *Carcinoma, Non-Small-Cell Lung/drug therapy/pathology/mortality; *Lung Neoplasms/drug therapy/pathology/mortality; Middle Aged; *Anaplastic Lymphoma Kinase/metabolism; *Lactams/therapeutic use; Aminopyridines; Aged; Adult; *Lactams, Macrocyclic/therapeutic use; Survival Rate; Follow-Up Studies; Protein Kinase Inhibitors/therapeutic use; Prognosis; Pyrazoles; ALK tyrosine kinase inhibitor; long-term safety; lorlatinib; non-small cell lung cancer; overall survival
Department(s)
Medical Oncology
Open Access at Publisher's Site
https://doi.org/10.1016/j.jtho.2024.11.021
Terms of Use/Rights Notice
Refer to copyright notice on published article.


Creation Date: 2024-12-12 03:22:39
Last Modified: 2025-05-15 04:17:35

© 2025 The Walter and Eliza Hall Institute of Medical Research. Access to this website is subject to our Privacy Policy and Terms of Use

An error has occurred. This application may no longer respond until reloaded. Reload 🗙